Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EPIX |
---|---|---|
09:32 ET | 2212 | 4.75 |
09:43 ET | 1450 | 4.64 |
09:45 ET | 160 | 4.59 |
09:52 ET | 139 | 4.59 |
09:56 ET | 241 | 4.59 |
10:24 ET | 141 | 4.63 |
10:28 ET | 400 | 4.6997 |
10:30 ET | 590 | 4.7 |
10:35 ET | 101 | 4.7 |
10:44 ET | 1746 | 4.72 |
10:46 ET | 755 | 4.75 |
10:51 ET | 527 | 4.8 |
10:55 ET | 600 | 4.97 |
11:02 ET | 100 | 4.865 |
11:04 ET | 200 | 4.96 |
11:09 ET | 300 | 4.95 |
11:13 ET | 400 | 4.9 |
11:15 ET | 400 | 5.03 |
11:18 ET | 600 | 4.9247 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ESSA Pharma Inc | 230.7M | -7.8x | --- |
Aldeyra Therapeutics Inc | 231.1M | -7.4x | --- |
Acrivon Therapeutics Inc | 233.1M | -2.6x | --- |
Pyxis Oncology Inc | 226.7M | -2.8x | --- |
Candel Therapeutics Inc | 225.6M | -5.9x | --- |
Actinium Pharmaceuticals Inc | 236.2M | -4.6x | --- |
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $230.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.86 |
EPS | $-0.63 |
Book Value | $3.30 |
P/E Ratio | -7.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.